Cancer, Covid19
Conditions
Brief summary
Serum antibody titre against COVID-19 spike protein will be measured before, after the first dose, and after the second dose (when applicable) in cancer patients who are receiving or received anti-cancer drugs. Side effects of vaccination and actual incidence of COVID-19 will be monitored.
Interventions
DRUGCOVID-19 vaccine
Subjects will be vaccinated with COVID-19 vaccines approved in Korea. Data on specific vaccines will be gathered.
Sponsors
Seoul National University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 20 years of age or older * Patients who are receiving or received anti-cancer drugs * Those who are not vaccinated against COVID-19 at the time of enrollment * Written informed consent
Exclusion criteria
* Any contraindications to COVID-19 vaccines * Those who were already vaccinated * Those who are on immunosuppressants or infected with HIV * Those who underwent organ transplantation * Active infections (for example, pneumonia)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Antibody titre after vaccination | 21-28 days after completion of vaccination | Antibody titre as measured by Anti-SARS-CoV-2 ELISA (IgG) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Antibody titer according to chemotherapy cycle, side effects, and use of corticosteroids or antipyretics | 21-28 days after completion of vaccination | Antibody titre as measured by Anti-SARS-CoV-2 ELISA (IgG) |
| Incidence of COVID-19 infection | 6 months after completion of vaccination | Incidence of actual COVID-19 infection |
Countries
South Korea
Outcome results
None listed